The prophylactic administration of a monoclonal antibody against human metapneumovirus attenuates viral disease and airways hyperresponsiveness in mice

Antiviral Therapy

Volumn 13, Issue 1, 2008, Pages 39-46

  Hamelin, Marie Eve ^a   Couture, Christian ^b   Sackett, Melanie ^b   Kiener, Peter ^c   Suzich, JoAnn ^c   Ulbrandt, Nancy ^c   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; MEDI 534; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 338; MOTAVIZUMAB; PALIVIZUMAB; UNCLASSIFIED DRUG; VIRUS RNA;

ACUTE PHASE RESPONSE; AIRWAY OBSTRUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BRONCHUS HYPERREACTIVITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; HISTOPATHOLOGY; HUMAN METAPNEUMOVIRUS; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS; LUNG FUNCTION; LUNG INTERSTITIUM; MOUSE; NONHUMAN; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; VIRUS INFECTION; VIRUS TITRATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BRONCHIAL HYPERREACTIVITY; DOSE-RESPONSE RELATIONSHIP, DRUG; METAPNEUMOVIRUS; MICE; PARAMYXOVIRIDAE INFECTIONS;

EID: 42149088203     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001; 7:719-724.
2. van den Hoogen BG, Bestebroer TM, Osterhaus AD, Fouchier RA. Analysis of the genomic sequence of a human metapneumovirus. Virology 2002; 295:119-132.
3. Biacchesi S, Skiadopoulos MH, Yang L, et al. Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol 2004; 78:12877-12887.
4. Skiadopoulos MH, Biacchesi S, Buchholz UJ, et al. Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. Virology 2006; 345:492-501.
5. Boivin G, Mackay I, Sloots TP, et al. Global genetic diversity of human metapneumovirus fusion gene. Emerg Infect Dis 2004; 10:1154-1157.
6. van den Hoogen BG, Herfst S, Sprong L, et al. Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 2004; 10:658-666.
7. Boivin G, De Serres G, Cote S, et al. Human metapneumovirus infections in hospitalized children. Emerg Infect Dis 2003; 9:634-640.
8. Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis 2003; 187:785-790.
9. Larcher C, Geltner C, Fischer H, Nachbaur D, Muller LC, Huemer HP. Human metapneumovirus infection in lung transplant recipients: clinical presentation and epidemiology. J Heart Lung Transplant 2005; 24:1891-1901.
10. Boivin G, De Serres G, Hamelin ME, et al. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis 2007; 44:1152-1158.
11. Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004; 350:443-450.
12. Williams JV, Wang CK, Yang CF, et al. The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J Infect Dis 2006; 193:387-395.
13. Hamelin ME, Cote S, Laforge J, et al. Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis 2005; 41:498-502.
14. Jartti T, van den Hoogen B, Garofalo RP, Osterhaus AD, Ruuskanen O. Metapneumovirus and acute wheezing in children. Lancet 2001; 360:1393-1394.
15. Schildgen O, Wilkesmann A, Simon A. Wheezing in patients with human metapneumovirus infection. J Allergy Clin Immunol 2006; 117:223.
16. Ebihara T, Endo R, Kikuta H, et al. Seroprevalence of human metapneumovirus in Japan. J Med Virol 2003; 70:281-283.
17. Wolf DG, Zakay-Rones Z, Fadeela A, Greenberg D, Dagan R. High seroprevalence of human metapneumovirus among young children in Israel. J Infect Dis 2003; 188:1865-1867.
18. Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother 2006; 50:774-777.
19. Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2003; 60:51-59.
20. Tang RS, Schickli JH, MacPhail M, et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3′ proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogeniciry. J Virol 2003; 77:10819- 10828.
21. Garcia-Garcia ML, Calvo C, Casas I, et al. Human metapneumovirus bronchiolitis in infancy is an important risk factor for asthma at age 5. Pediatr Pulmonol 2007; 42:458-464.
22. Hamelin ME, Prince GA, Gomez AM, Kinkead R, Boivin G. Human metapneumovirus infection induces long-term pulmonary inflammation associated with airway obstruction and hyperresponsiveness in mice. J Infect Dis 2006; 193:1634-1642.
23. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532-540.
24. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-537.
25. Mejias A, Chavez-Bueno S, Rios AM, et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother 2005; 49:4700-4707.
26. Ulbrandt ND, Ji H, Patel NK, et al. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol 2006; 80:7799-7806.
27. Deffrasnes C, Cote S, Boivin G. Analysis of replication kinetics of the human metapneumovirus in different cell lines by real-time PCR. J Clin Microbiol 2005; 43:488-490.
28. Darniot M, Petrella T, Aho S, Pothier P, Manoha C. Immune response and alteration of pulmonary function after primary human metapneumovirus (hMPV) infection of BALB/c mice. Vaccine 2005; 23:4473-4480.
29. Skiadopoulos MH, Biacchesi S, Buchholz UJ, et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol 2004; 78:6927-6937.
30. Ma X, Endo R, Ebihara T, Ishiguro N, Ishiko H, Kikuta H. Production and characterization of neutralizing monoclonal antibodies against human metapneumovirus F protein. Hybridoma 2005; 24:201-205.
31. Alvarez R, Harrod KS, Shieh WJ, Zaki S, Tripp RA. Human metapneumovirus persists in BALB/c mice despite the presence of neutralizing antibodies. J Virol 2004; 78:14003-14011.
32. Hamelin ME, Yim K, Kuhn KH, et al. Pathogenesis of human metapneumovirus lung infection in BALB/c mice and cotton rats. J Virol 2005; 79:8894-8903.
33. Jafri HS, Chavez-Bueno S, Mejias A, et al. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis 2004; 189:1856-1865.
34. Kuiken T, van den Hoogen BG, van Riel DA, et al. Experimental human metapneumovirus infection of cynomolgus macaques (Macaca fascicularis) results in virus replication in ciliated epithelial cells and pneumocytes with associated lesions throughout the respiratory tract. Am J Pathol 2004; 164:1893-1900.
35. MacPhail M, Schickli JH, Tang RS, et al. Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design. J Gen Virol 2004; 85:1655-1663.
36. Mejias A, Chavez-Bueno S, Rios AM, et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother 2004; 48:1811-1822.
37. Ottolini MG, Curtis SR, Mathews A, Ottolini SR, Prince GA. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant 2002; 29:117-120.
38. Prince GA, Mathews A, Curtis SJ, Porter DD. Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model with systemically administered monoclonal antibody (Palivizumab) and glucocorticosteroid. J Infect Dis 2000; 182:1326-1330.
39. Hamelmann E, Schwarze J, Takeda K, et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997; 156:766-775.
40. Hogg JC. Childhood viral infection and the pathogenesis of asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 1999; 160:S26-S28.
41. Openshaw PJ, Dean GS, Culley FJ. Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatr Infect Dis J 2003; 22:S58-S64.
42. Simoes EA, Carbonell-Estany X, Kimpen J, et al. 14th European Respiratory Society Annual Congress 4-8 September 2004, Glasgow, UK: abstract 1349.